ETS transcription factors: Possible targets for cancer therapy
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Ets family (ETS) transcription factors, characterized by an evolutionally conserved Ets domain, play important roles in cell development, cell differentiation, cell proliferation, apoptosis and tissue remodeling. Most of them are downstream nuclear targets of Ras‐MAP kinase signaling, and the deregulation of ETS genes results in the malignant transformation of cells. Several ETS genes are rearranged in human leukemia and Ewing tumors to produce chimeric oncoproteins. Furthermore, the aberrant expression of several ETS genes is often observed in various types of human malignant tumors. Considering that some ETS transcription factors are involved in malignant transformation and tumor progression, including invasion, metastasis and neo‐angiogenesis through the activation of cancer‐related genes, they could be potential molecular targets for selective cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities
McKercher, S. R., Torbett, B. E., Anderson, K. L., Henkel, G. W., Vestal, D. J., Baribault, H., Klemsz, M., Feeney, A. J., Wu, G. E., Paige, C. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00949.x · Cited by 1,130
The ETS-domain transcription factor family
Sharrocks, A. D. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35099076 · Cited by 1,086
Transcription Factors, Normal Myeloid Development, and Leukemia
Tenen, D. G., Hromas, R., Licht, J. D., & Zhang, D.-E. (1997) · Blood · doi:10.1182/blood.v90.2.489 · Cited by 735
PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors
Nerlov, C., & Graf, T. (1998) · Genes & Development · doi:10.1101/gad.12.15.2403 · Cited by 449
PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding
Zhang, P., Zhang, X., Iwama, A., Yu, C., Smith, K. A., Mueller, B. U., Narravula, S., Torbett, B. E., Orkin, S. H., & Tenen, D. G. (2000) · Blood · doi:10.1182/blood.v96.8.2641 · Cited by 368
Specificity within the ets Family of Transcription Factors
(1998) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60738-1 · Cited by 344
Ets ternary complex transcription factors
Buchwalter, G., Gross, C., & Wasylyk, B. (2004) · Gene · doi:10.1016/j.gene.2003.09.028 · Cited by 336 · cited 1×
“TEL Chromosome translocation (TEL-PDGFRβ) CMMoL [t(5;12)]”
Retinoids in cancer therapy and chemoprevention: Promise meets resistance
Freemantle, S. J., Spinella, M. J., & Dmitrovsky, E. (2003) · Oncogene · doi:10.1038/sj.onc.1206936 · Cited by 312
Vangala, R. K., Heiss-Neumann, M. S., Rangatia, J. S., Singh, S. M., Schoch, C., Tenen, D. G., Hiddemann, W., & Behre, G. (2003) · Blood · doi:10.1182/blood-2002-04-1288 · Cited by 245
Heterozygous PU.1 mutations are associated with acute myeloid leukemia
Mueller, B. U., Pabst, T., Osato, M., Asou, N., Johansen, L. M., Minden, M. D., Behre, G., Hiddemann, W., Ito, Y., & Tenen, D. G. (2002) · Blood · doi:10.1182/blood.v100.3.998 · Cited by 243
Göttgens, B., Nastos, A., Kinston, S., Piltz, S., Delabesse, E. C. M., Stanley, M., Sanchez, M., Ciau‐Uitz, A., Patient, R., & Green, A. R. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf286 · Cited by 212 · cited 8×
“These translocations are t(11;22)(q24;q12) (EWS-Fli-1), t(21;22)(q22;q12) (EWS-Erg), t(17;22)(q12;q12) (EWS-E1AF) and t(7;22)(p22;q12) (EWS-ER81).”
BackgroundInfluentialSpi-1/PU.1 Transgenic Mice Develop Multistep Erythroleukemias
Moreau-Gachelin, F., Wendling, F., Molina, T., Denis, N., Titeux, M., Grimber, G., Briand, P., Vainchenker, W., & Tavitian, A. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.5.2453 · Cited by 189
Physical and functional interactions between the transcription factor PU.1 and the coactivator CBP
Yamamoto, H., Kihara-Negishi, F., Yamada, T., Hashimoto, Y., & Oikawa, T. (1999) · Oncogene · doi:10.1038/sj.onc.1202427 · Cited by 113
Self-citationOikawa, T., Yamada, T., Kihara-Negishi, F., Yamamoto, H., Kondoh, N., Hitomi, Y., & Hashimoto, Y. (1999) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400534 · Cited by 109
Self-citationSuzuki, M., Yamada, T., Kihara-Negishi, F., Sakurai, T., & Oikawa, T. (2003) · Oncogene · doi:10.1038/sj.onc.1207182 · Cited by 87
Self-citationKihara-Negishi, F., Yamamoto, H., Suzuki, M., Yamada, T., Sakurai, T., Tamura, T., & Oikawa, T. (2001) · Oncogene · doi:10.1038/sj.onc.1204756 · Cited by 69
Self-citationYamada, T., Kihara-Negishi, F., Yamamoto, H., Yamamoto, M., Hashimoto, Y., & Oikawa, T. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4251 · Cited by 35
Self-citation
Cited by
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Kao, J., Salari, K., Bocanegra, M., Choi, Y.-L., Girard, L., Gandhi, J., Kwei, K. A., Hernandez-Boussard, T., Wang, P., Gazdar, A. F., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006146 · Cited by 788
“The basal-A subtype exhibited enriched expression of ETS pathway genes, a pathway linked to diverse tumor phenotypes including invasion and metastasis [78].”
BackgroundChen, N., Zhao, G., Yan, X., Lv, Z., Yin, H., Zhang, S., Song, W., Li, X., Li, L., Du, Z., et al. (2018) · Genome Biology · doi:10.1186/s13059-018-1594-y · Cited by 436
Wang, J., Cai, Y., Ren, C., & Ittmann, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1966 · Cited by 404
Signaling mechanisms, interaction partners, and target genes of STAT6
HEBENSTREIT, D., WIRNSBERGER, G., HOREJSHOECK, J., & DUSCHL, A. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.01.004 · Cited by 308
Metadata
- Authors
- Oikawa, T.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2004-08
- Volume
- 95
- Issue
- 8
- Pages
- 626-633
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2056372829
- Cited by
- 184
- References
- 18
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.